Eligibility of the Systolic Blood Pressure Intervention Trial (SPRINT) to the Chinese Adults

Table 3

Antihypertensive medication usage among hypertensive participants by overall and those eligible for SPRINT.

	Overall	SPRINT eligible
Hypertension
Sample,	11,637	3,494
Number of classes^1
0	8,336 (71.6%)	2,268 (64.9%)
1	2,614 (22.5%)	1,004 (28.7%)
2	611 (5.2%)	203 (5.8%)
≥3	76 (0.7%)	19 (0.6%)
Treated hypertension
Sample,	3,301	1,225
Western medicine
ACE inhibitor	566 (17.2%)	170 (13.9%)
Angiotensin receptor blocker	29 (0.9%)	11 (0.9%)
Beta-blocker	240 (7.3%)	88 (7.2%)
Calcium-channel blocker	1,197 (36.3%)	419 (34.2%)
Diuretic	1,443 (43.7%)	560 (45.7%)
Others^2	115(3.5%)	33(2.7%)
TCM-West compound	441 (13.4%)	173 (14.1%)
TCM only^3	56(1.7%)	16(1.3%)

Reported as or number (%). Abbreviations: ACE: angiotensin-converting enzyme. SPRINT: Systolic Blood Pressure Intervention Trial. TCM: Traditional Chinese medicine. ¹Number of antihypertensive medication classes included ACE inhibitors, alpha blockers, aldosterone receptor antagonists, angiotensin receptor-blockers, beta-blocker, calcium-channel blockers, central-acting agents, diuretic, renin inhibitors, direct acting vasodilators, and TCM-West compound. ²Others included alpha blockers, aldosterone receptor antagonists, central-acting agents, direct acting vasodilators, and TCM-West compound. ³TCM only group was not considered an antihypertensive medication class when setting SBP criteria.